[CSCO2014]肝癌靶向治疗:除了索拉非尼还有什么?——Ghassan K. Abou-Alfa教授访谈

作者:  G.K.Abou-Alfa   日期:2014/10/28 16:17:57  浏览量:14249

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

专家简介:   Ghassan K. Abou-Alfa,MD,斯隆凯瑟琳纪念癌症中心。主要从事原发性肝癌以及胰腺、胆囊和胆管肿瘤的诊疗,在利用新型癌症生物靶向药物治疗化疗耐受性胃肠道肿瘤,特别是肝胆和胰腺肿瘤,提高癌症治疗疗效方面做了大量工作。

  Oncology Frontier: Now we are in a target therapy era for cancer, however, when we talk about HCC, the options are very poor. We are eager for something besides sorafenib. Why is it so difficult to develop a new drug for the treatment of HCC?

  《肿瘤瞭望》:现今我们处于肿瘤靶向药物的时代,然而,只要当提到肝细胞癌,能选择的药物却很有限。我们希望能看到除了索拉非尼外的其他药物,为何开发治疗肝细胞癌新药这么困难?

  Dr Abou-Alfa: You are right. These have been very difficult years after sorafenib was approved in 2007. Since then, many trials have been conducted and all of them so far have been negative at trying to overcome that ceiling of the anti-angiogenesis therapy with sorafenib where the mean survival is only 10.7 months. I personally think that hope is still there. Two of the options we have are combination therapies. I would like to mention the sorafenib plus doxorubicin versus sorafenib alone clinical trial that we are conducting in the US as part of the NCI efforts. In addition to that, I look forward to seeing different targets other than anti-angiogenic being looked at in the first line setting. Obviously in the second line setting, despite the discouraging news of the three negative clinical trials, there are many others ongoing and we will await those results.

  阿布阿尔法博士:是的。自从2007年索拉非尼被临床认可后,相关的研究一直都很难。自从那时候起,许多药物的相关临床试验研究一直都在开展,结果却表明与索拉非尼联用对抗肝癌细胞血管形成治疗方面无效,总体中位生存期只有10.7个月。但我个人认为两种药物联合治疗肝细胞癌还是有希望的,现在美国正在开展索拉非尼联合阿霉素与单独使用索拉非尼相对照的临床试验,这将作为美国国家癌症研究院研究的一部分。除此之外,我期望能看到除抗血管生成药物以外的其他不同类型的靶向药物应用于临床一线。尽管Ⅲ期临床试验阴性结果不如人意,还是有很多临床Ⅱ期研究正在进行,我们也很期待研究结果。

  Oncology Frontier: How many kinds of novel agents are under investigation in phase III trials in advanced HCC?

  《肿瘤瞭望》:有多少种新型药物正在进行肝细胞癌治疗的Ⅲ期临床研究?

  Dr Abou-Alfa: At the moment, in the first line setting, there are two in phase III trials and in the phase III setting for second line therapy, there are three. So there is quite a bit of activity. It is just a matter of waiting for results.

  阿布阿尔法博士:目前进入Ⅲ期临床试验的一线药物有两种,二线药物有三种。所以我们还是做了许多相关工作的,只是结果尚需要时间等待。

  Oncology Frontier: Which one of these novel agents under investigation is most promising for advanced HCC?

  《肿瘤瞭望》:在您看来,哪种药物在治疗肝癌方面可能最有效?

  Dr Abou-Alfa: That is a very difficult question. I would not be able to answer as these trials are still ongoing and we will have to wait for the results. The good news is that there is quite a bit of diversity in regard to the targets we are looking at and that reassures us that ultimately we will find the right one.

  阿布阿尔法博士:这个问题现在很难回答,临床试验还在进行中,我想试验结果会给我们答案。有个好消息就是,靶向药物的研究靶点是多样化的,最终我们总会找到最合适的那个靶点。

版面编辑:张楠  责任编辑:吉晓蓉


肝细胞癌索拉非尼靶向治疗

分享到: 更多